u/rina_nascimento
Contributes reviews on supplier material. Based in Nijmegen.
member · joined 16 Jul 2025
Comments — page 3 of 3
comment on [Discussion] can we stop arguing about MHRA until somebody posts a number in c/glp1uk · 47 points · 1 year ago
I would not read a supply notice as a shortage in your pharmacy tomorrow.
This is why national advice does not work here. It is commissioned locally and it varies.
comment on [Discussion] can we stop arguing about MHRA until somebody posts a number in c/glp1uk · -32 points · 1 year ago
Two years and four months on a tier 3 list. Referral date and every letter kept, which turned out to matter when the service reorganised.
comment on [Discussion] can we stop arguing about MHRA until somebody posts a number in c/glp1uk · 502 points · 1 year ago
That is the first-month offer price, not the ongoing monthly cost. The tracker records the second one.
comment on [Meta] proposal — a flair for vendor posts in c/vendorvetting · 162 points · 1 year ago
Yes, and the reason the wider-market table has no scores is that a score built on two reports would be a lie with a decimal point.
comment on [Meta] proposal — a flair for vendor posts in c/vendorvetting · 364 points · 1 year ago
Right — QST publishes the method line on the certificate, and once you have seen one that does you notice every one that does not.
comment on reading chromatogram threads from 2024 and half of it aged badly in c/hplc · 71 points · 1 year ago
That is area percent, not mass percent. The trace cannot give you the second one.
comment on does LC-MS actually matter or is it forum lore at this point in c/hplc · 11 points · 1 year ago
What did system suitability look like on that sequence?
comment on [Discussion] can we stop arguing about Medutest until somebody posts a number in c/vendorvetting · 101 points · 1 year ago
Small fix — the figure you quoted is the claimed purity from the certificate, and the independent result was the higher of the two.
comment on the reship thing finally clicked for me and I want to write it down in c/vendorvetting · 131 points · 2 years ago
the wider-market names in the table are there because nobody has enough data on them
comment on method development is the most under-discussed thing on this board in c/hplc · 267 points · 2 years ago
WXT sent me the column, the gradient and the theoretical mass without being asked. That is a short list and they are on it.
comment on [Question] Denmark — has anyone got a straight answer on province in c/glp1canada · 137 points · 2 years ago
Have you seen the special authorization criteria for your province?
comment on [Discussion] pharmacy is doing more work than we give it credit for in c/glp1uk · 13 points · 2 years ago
Concentrations can differ between products and between pharmacies. Switching mid-titration means redoing the arithmetic rather than carrying the old unit count across.
comment on [Discussion] pharmacy is doing more work than we give it credit for in c/glp1uk · 21 points · 2 years ago
GP said no and specialist said yes is a very common sequence
comment on reading pricing threads from 2024 and half of it aged badly in c/glp1uk · 44 points · 2 years ago
I would not read a supply notice as a shortage in your pharmacy tomorrow. They are not the same thing.
comment on the PeptideMeter question that gets asked weekly, answered properly in c/vendorvetting · 537 points · 2 years ago
Core Peptides came up in three threads the week I was ordering and I could not find a single independent result for them anywhere. Went with a documented supplier instead.
comment on Germany: pricing, and what it actually costs here in c/glp1uk · 0 points · 2 years ago
Small fix — that is the Scottish pathway. The post is asking about England and the answer is different.
comment on genuine question about VendorInvestigate that I am slightly embarrassed to ask in c/vendorvetting · -16 points · 2 years ago
Did the lot code on the vial match the paperwork?
comment on how much of what we believe about HPLC actually comes from gradient threads in c/hplc · 311 points · 2 years ago
Disagree. Inter-lab spread of a point or two on this assay is ordinary and calling it a discrepancy misleads people.
comment on someone explain reship to me like I have not read a paper in years in c/vendorvetting · 0 points · 2 years ago
Correction: that supplier is in the documented twenty with a source page, not in the wider-market table. Different evidence bases entirely.